格陵兰人群中的血脂异常及其预防潜力。

Dyslipidemia and the preventive potential in the Greenlandic population.

作者信息

Bundgaard Johan Skov, Jørgensen Marit E, Andersen Kristine, Bundgaard Henning, Geisler Uka Wilhjelm, Pedersen Michael Lynge

机构信息

Queen Ingrid Primary Health Care Centre, Nuuk, Greenland.

Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

出版信息

Atheroscler Plus. 2022 Dec 27;51:22-27. doi: 10.1016/j.athplu.2022.12.003. eCollection 2023 Mar.

DOI:10.1016/j.athplu.2022.12.003

PMID:36969703

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10037086/

Abstract

BACKGROUND

Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for development of cardiovascular diseases. Based on available clinical data, we aimed to investigate the plasma lipid profile in the Greenlandic population, the proportion on cholesterol-lowering treatment and the adherence to local indications for cholesterol-lowering therapy.

METHODS

This is an observational cross-sectional study of the adult (≥21 years) Greenlandic population with focus on clinically determined lipid levels from 2017 to early 2022. We investigated levels of dyslipidemia and assessed cholesterol-lowering medication usage in individuals with an indication according to current Greenlandic guidelines, which include a) LDL-C >5 mmol/l, b) diabetes, c) diagnosed atherosclerotic disease and 4) a SCORE2 >7.5%.

RESULTS

In the adult Greenlandic population of 40,565 individuals a lipid profile was available in 13,895 with a mean LDL-C of 3.0 mmol/L and 976 (7%) had a LDL-C >5 mmol/l. One or more indications for cholesterol-lowering medication was present in 3988 individuals and a total of 5464 adult Greenlanders either fulfilled local criteria for statin therapy or received a statin (some without current indication) and among these, 2232 (41%) individuals received no statin.

CONCLUSION

These findings indicate that clinically significant dyslipidemia is common in the adult Greenlandic population and that the cardiovascular preventive potential of cholesterol-lowering therapy is currently underutilized.

摘要

背景

低密度脂蛋白胆固醇（LDL-C）是已明确的心血管疾病发生风险因素。基于现有临床数据，我们旨在调查格陵兰人群的血浆脂质谱、接受降胆固醇治疗的比例以及对当地降胆固醇治疗指征的依从性。

方法

这是一项针对成年（≥21岁）格陵兰人群的观察性横断面研究，重点关注2017年至2022年初临床测定的血脂水平。我们调查了血脂异常水平，并根据当前格陵兰指南评估了有指征个体的降胆固醇药物使用情况，这些指征包括：a）LDL-C>5 mmol/L，b）糖尿病，c）诊断为动脉粥样硬化疾病，以及4）SCORE2>7.5%。

结果

在40565名成年格陵兰人群中，13895人有血脂谱，平均LDL-C为3.0 mmol/L，976人（7%）的LDL-C>5 mmol/L。3988人有一个或多个降胆固醇药物使用指征，共有5464名成年格陵兰人符合他汀类药物治疗的当地标准或接受了他汀类药物治疗（一些人无当前指征），其中2232人（41%）未接受他汀类药物治疗。